We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » US Oncology Pushing CMS to Revise CAP Process for Part B Drugs
US Oncology Pushing CMS to Revise CAP Process for Part B Drugs
August 10, 2005
The Centers for Medicare & Medicaid Services’ (CMS) proposed competitive acquisition program (CAP) for Medicare Part B drugs is flawed and could leave physicians and vendors open to substantial risks, according to cancer services network US Oncology, which is pressuring the agency to revise the program.